Patent ID: 11963965
Assignee: NATIONAL JEWISH HEALTH
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating a cystic fibrosis transmembrane conductance regulator (CFTR)-mediated disease in a human patient, comprising administering to the patient an effective amount of a CFTR activator or a pharmaceutically acceptable salt thereof, and an effective amount of a CFTR potentiator and/or at least one CFTR corrector; wherein the CFTR activator is lubiprostone or a pharmaceutically acceptable salt thereof, the CFTR potentiator is VX-770 (Ivacaftor), and wherein the CFTR corrector is selected from the group consisting of VX-809 (lumacaftor), VX-661 (tezacaftor), VX-445 (elexacaftor) and combinations thereof.